Zyngenia Inc.
http://www.zyngenia.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Zyngenia Inc.
BIO 2013 Tuesday Roundup: Reimbursement Reigns, Industry Innovation, New Antibodies
Our survey of news and notes from the second day of the BIO conference includes discussions of changes in the way pharma negotiates milestones, big ambitious projects to solve industry “dysfunction,” and a next-generation antibody developer pushing toward the clinic.
Is The Time Finally Right For Bispecific Antibodies?
Merck, Lilly, Gilead and Celgene are among the companies striking deals that involve bispecific antibodies. The novel dual-acting drugs have been in development since the 1980s with little success, yet big pharma believes they may finally be coming of age.
Start-Up Execs On The Move, July-August 2012
Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.
Start-Up Execs On The Move, May 2012
Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice